Novo Nordisk A/S
Excess weight loss drug contender Zealand Pharma jumps 23% on demo success
Vials on the Wegovy line at the Novo Nordisk A/S production facilities in Hillerod, Denmark, on Friday, March 8, 2024. Bloomberg | Bloomberg | Getty Photos LONDON — Shares of Denmark’s Zealand Pharma popped approximately 23% in Friday early morning deals, notching a record higher soon after an early-phase analyze of its fat decline drug […]
Read More
Healthy Returns: More U.S. employers are now covering GLP-1s for weight loss
Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. The injectable weight loss medication Wegovy at New City Halstead Pharmacy in Chicago on April 24, 2024. Scott Olson | Getty Images Good morning! More U.S. employers are covering a buzzy class of medications called GLP-1s for weight […]
Read More
How Eli Lilly is managing soaring demand for GLP-1s, according to outgoing CFO Anat Ashkenazi
A pharmacist holds boxs of Eli Lilly & Co. Mounjaro brand tirzepatide medication arranged at a pharmacy in Provo, Utah, US, on Monday, Nov. 27, 2023. George Frey | Bloomberg | Getty Images Skyrocketing demand for a class of weight loss and diabetes treatments has lifted Eli Lilly to new heights over the last year. […]
Read More
Why half of all workers may struggle to get weight-loss drug health insurance coverage
An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City on Dec. 11, 2023. Brendan McDermid | Reuters Companies are increasing access to new blockbuster weight-loss drugs for employees, but size of employer may make a big difference in early access. Small businesses and their workers are often stuck […]
Read More
Telehealth company Ro launches GLP-1 supply tracker to help patients navigate shortages
GLP-1 Supply Tracker from Ro. Courtesy: Ro Telehealth company Ro on Wednesday launched a new tracker to help patients find a popular class of weight loss and diabetes drugs called GLP-1s amid shortages of those treatments in the U.S. The supply tracker could be a valuable tool for many Americans scrambling to get their hands […]
Read More
This new weight loss drug ETF bets big on two of the industry’s leading players
ETF Edge This new weight loss drug ETF bets big on two of the industry’s leading players Published Mon, May 27 202412:01 PM EDT Anna Gleason@anna_gle WATCH LIVE Source
Read More
How digital health companies are capitalizing on the GLP-1 boom
Patent protection for Wegovy — Novo Nordisk’s blockbuster weight loss drug, which contains the second generation GLP-1 active ingredient and is at least twice as effective — is expected to expire by the decade’s end. Michael Siluk | UCG | Getty Images For Gray Beard, a kindergarten teacher in Charlotte, North Carolina, losing weight had […]
Read More
Eli Lilly’s big GLP-1 investment — plus, what we want from 4 portfolio stock earnings
Every weekday the CNBC Investing Club with Jim Cramer holds a “Morning Meeting” livestream at 10:20 a.m. ET. Here’s a recap of Friday’s key moments. 1. Wall Street was bouncing higher Friday after, as Jim Cramer put it, a “really bad day” in the prior session. Thursday’s late-day decline happened as bond yields rose on […]
Read More
Healthy Returns: Eli Lilly, Novo Nordisk are competing to develop more convenient weekly insulins
A patient injects herself with an insulin pen. Guido Krzikowski | Bloomberg | Getty Images Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good afternoon! The rivalry between Eli Lilly and Novo Nordisk extends beyond a buzzy class of weight loss and diabetes drugs called GLP-1s. […]
Read More
AstraZeneca targets $80 billion in total revenue by 2030 in ‘post-Covid era’
The Astrazeneca logo is pictured at the World Artificial Intelligence Conference 2021 in Shanghai, China, July 7, 2021. Costfoto | Future Publishing | Getty Images LONDON — Pharmaceutical company AstraZeneca on Tuesday said it planned to increase its total revenue to $80 billion by 2030 — up 75% from $45.8 billion in 2023. “We have […]
Read More